BPC-157 vs TB-500
BPC-157 and TB-500 are both research-stage peptides with proposed tissue-repair properties, and they are among the most commonly co-administered compounds in the biohacking and recovery community. Despite their similar reputation, they differ meaningfully in origin, mechanism, and the body of preclinical evidence supporting them. Neither has established human clinical trial data for any therapeutic indication.
Side-by-side comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Mechanism class | Gastric-derived pentadecapeptide; NO-pathway & VEGF modulator | Thymosin β-4 fragment; actin-sequestering & angiogenic signaling |
| FDA status | Not approved — research chemical | Not approved — research chemical |
| Evidence tier | Tier 3–4 (animal studies + 1 human pilot, n=2) | Tier 3 (animal models; no human trials) |
| Typical dosing | 250–500 mcg/day SC or IM (community-reported) | 2–2.5 mg twice weekly SC (community-reported) |
| Half-life | ~20–30 min (IV); SC extends effective window | Not established in humans |
| Common side effects |
|
|
| Common stacks | TB-500, Ipamorelin | BPC-157, GHK-Cu |
| Approx. cost | ~$30–80 per vial (research vendor) | ~$40–100 per vial (research vendor) |
Key differences
- 1
BPC-157 is a 15-amino-acid sequence derived from a gastric protective protein; TB-500 is a 7-amino-acid fragment of thymosin beta-4, a protein involved in actin sequestration and cytoskeletal remodeling — distinct molecular origins and targets.
- 2
BPC-157 has a broader preclinical evidence base across tendon, muscle, bone, gut, and nerve tissue; TB-500 evidence centers primarily on cardiac tissue repair and angiogenesis models.
- 3
BPC-157 is typically dosed at microgram quantities daily; TB-500 protocols use milligram quantities twice weekly — roughly a 10× dose difference by weight.
- 4
Their proposed mechanisms are complementary (BPC-157 via NO/VEGF; TB-500 via actin/angiogenesis), which is why they are frequently stacked — though no human data support or refute this combination.
- 5
Neither compound has completed a human clinical trial for any indication; all efficacy claims derive from animal models or anecdotal reports.
Which might be better for…
Tendon and ligament recovery
Both appear in animal studies of connective tissue repair, with BPC-157 having the larger volume of published rodent data across diverse injury types. TB-500 showed cardiac muscle and angiogenesis effects in animal models. For tendon-focused recovery research, BPC-157 has the stronger (if still preclinical) evidence base.
Gut and mucosal healing
BPC-157 has a substantially stronger preclinical rationale for gastrointestinal applications, with studies in gastric ulcer, IBD-like inflammation, and fistula models. TB-500 does not have meaningful published evidence in gut tissue. Users interested in this specific application will find more (though still animal-only) literature supporting BPC-157.
Stacking both for systemic tissue support
Many self-experimenting users run BPC-157 and TB-500 simultaneously, reasoning that their non-overlapping mechanisms provide additive benefit. TB-500 targets actin/cytoskeletal signaling; BPC-157 targets NO-pathway and VEGF expression. There is no human evidence for or against this approach; risk is unknown.